Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Research & Development (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Research & Development over the past 16 years, most recently at $2.1 million for Q2 2025.

  • Quarterly results put Research & Development at $2.1 million for Q2 2025, down 2.68% from a year ago — trailing twelve months through May 2025 was $8.3 million (down 3.7% YoY), and the annual figure for FY2025 was $8.3 million, down 3.7%.
  • Research & Development for Q2 2025 was $2.1 million at Lifecore Biomedical, Inc. \De\, up from $2.0 million in the prior quarter.
  • Over the last five years, Research & Development for LFCR hit a ceiling of $2.3 million in Q1 2022 and a floor of $1.2 million in Q2 2021.
  • Median Research & Development over the past 5 years was $2.1 million (2022), compared with a mean of $2.0 million.
  • Peak annual rise in Research & Development hit 243.69% in 2021, while the deepest fall reached 40.41% in 2021.
  • Lifecore Biomedical, Inc. \De\'s Research & Development stood at $1.7 million in 2021, then rose by 29.58% to $2.2 million in 2022, then dropped by 3.63% to $2.1 million in 2023, then fell by 8.29% to $1.9 million in 2024, then rose by 9.3% to $2.1 million in 2025.
  • The last three reported values for Research & Development were $2.1 million (Q2 2025), $2.0 million (Q1 2025), and $1.9 million (Q4 2024) per Business Quant data.